Tempest Therapeutics, Inc. — Form 8-K
Filed October 19, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Tempest Therapeutics appointed John W. Frederick to its board of directors effective October 14, 2026. Frederick brings 30+ years of executive experience including CFO roles at Skillsoft and Indigo Ag, COO/CFO roles at Snagajob, and current board service at MutualOne Bank and SenSanna. No compensation terms, equity grants, or material agreements were disclosed in the filing.
Why this rating
Standard board appointment with no quantified financial impact. Director adds financial/capital expertise; no new financing, dilution, or operational change disclosed.
See more from October 19, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.